SARS-CoV-2 infection is dependent on viral entry into the host cell, a process mediated by binding of the viral spike (S) protein receptor-binding domain (RBD) to ACE2 present on the host cells. A better understanding of this process will aid in vaccine and drug development to combat COVID-19. We’ve released a number of new recombinant proteins and antibodies to enable this research, including:
Try our new SARS-CoV-2-specific Flex-T™ MHC reagents to simplify your protocol and save time. Each HLA monomer comes ready-to-use with fixed relevant SARS-CoV-2 peptides, removing the need for a peptide exchange step.
Login/Register 
United States ($) USD
Austria (€) EUR
Belgium (€) EUR
Finland (€) EUR
France (€) EUR
Germany (€) EUR
Ireland (€) EUR
Japan (¥) JPY
Luxembourg (€) EUR
Netherlands (€) EUR
Switzerland (CHF) CHF
United Kingdom (£) GBP
Follow Us